Tianze Jiao, Ph.D.
Assistant Professor
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 273-9933
Business Email:
tianzejiao@ufl.edu
About Tianze Jiao
Tianze Jiao received his Ph.D. from the University of Utah. Recently, he accomplished his postdoctoral fellowship from the McGill University and joined the faculty of UF in 2022.
Dr. Jiao is a pharmacoepidemiologist with a focus on cardiovascular, and cardiometabolic diseases. In order to generate real-world evidence to facilitate precision medicine, he conducts research using large databases (i.e., electronic health records and claims data) and advanced analytics (i.e., causal inference modeling, adaptive treatment strategy, and machine learning) to 1) identify and address time-related bias in the real-world data; 2) assess comparative effectiveness/safety, and heterogeneous effects of interventions, as well as drug-drug interactions. His research programs and collaborations have been funded by the Canadian Institutes of Health Research, CDC, and the Bill & Melinda Gates Foundation.
Keywords: Pharmacoepidemiology, Big Data, Adaptive treatment strategy, Machine learning, Cardiology
Teaching Profile
Courses Taught
2023-2025
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2023-2025
PHA6910 Supervised Research
2023-2025
PHA5223 P-Epidem Drug Safety
2023-2025
PHA6938 Research Seminar
2024-2025
PHA6268 Pharmacoepidemiology and Patient Safety
2024-2025
PHA6971 Research for Master’s Thesis
2024-2025
PHA6717 Measurement in Pharmaceutical Outcomes and Policy Research
2024-2025
PHA7979 Advanced Research
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-2608-616X
Publications
Academic Articles
2025
Association Between Use of WATCHMAN Device and 1-Year Mortality Using High-Dimensional Propensity Scores to Reduce Confounding
Circulation: Cardiovascular Quality and Outcomes.
18(4)
[DOI] 10.1161/circoutcomes.124.011188.
2025
Disparities in Clinical Outcomes Observed Within Electronic Health Record Data From a Statewide Cohort of Pulmonary Arterial Hypertension Patients.
Pulmonary circulation.
15(1)
[DOI] 10.1002/pul2.70041.
[PMID] 39811577.
2024
5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
Diabetes, obesity & metabolism.
26(2):463-472
[DOI] 10.1111/dom.15332.
[PMID] 37867175.
2024
Association between low cognitive performance and diabetes-related health indicators across racial and ethnic groups in adults with diabetes.
Diabetes, obesity & metabolism.
26(9):3723-3731
[DOI] 10.1111/dom.15715.
[PMID] 38899435.
2024
Associations Between Postdischarge Care and Cognitive Impairment-Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia in Adults With Diabetes.
Diabetes care.
47(2):225-232
[DOI] 10.2337/dca23-0013.
[PMID] 38048487.
2024
Development of breakthrough bleeding model of combined-oral contraceptives utilizing model-based meta-analysis.
CPT: pharmacometrics & systems pharmacology.
13(11):2016-2025
[DOI] 10.1002/psp4.13261.
[PMID] 39551952.
2024
Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post-hoc machine learning analysis of ACCORD trial data.
Diabetes, obesity & metabolism.
26(4):1502-1509
[DOI] 10.1111/dom.15453.
[PMID] 38297986.
2024
Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005-2019.
Primary care diabetes.
18(5):561-563
[DOI] 10.1016/j.pcd.2024.07.003.
[PMID] 39095227.
2023
Letter by Jiao and Ruzieh Regarding Article, “Comparative Effectiveness of Left Atrial Appendage Occlusion Versus Oral Anticoagulation by Sex”.
Circulation.
148(6):508-509
[DOI] 10.1161/CIRCULATIONAHA.123.064702.
[PMID] 37549202.
2023
Use of a Statistical Adaptive Treatment Strategy Approach for Emulating Randomized Controlled Trials Using Observational Data: The Example of Blood-Pressure Control Strategies for the Prevention of Cardiovascular Events Among Individuals With Hypertension at High Cardiovascular Risk.
American journal of epidemiology.
192(9):1576-1591
[DOI] 10.1093/aje/kwad091.
[PMID] 37073411.
2022
Identifying asthma patients at high risk of exacerbation in a routine visit: A machine learning model.
Respiratory medicine.
198
[DOI] 10.1016/j.rmed.2022.106866.
[PMID] 35594754.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare.
Diabetes care.
45(8):1814-1821
[DOI] 10.2337/dc21-2601.
[PMID] 35700384.
2021
Predictors of Asthma Control and Exacerbations: A Real-World Study.
The journal of allergy and clinical immunology. In practice.
9(7):2802-2811.e2
[DOI] 10.1016/j.jaip.2021.04.049.
[PMID] 33962067.
2021
Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention among Patients with Hypertension in the United Kingdom.
American journal of hypertension.
[DOI] 10.1093/ajh/hpab137.
[PMID] 34448818.
2014
Real-world evidence in pain research: a review of data sources.
Journal of pain & palliative care pharmacotherapy.
28(3):294-304
[DOI] 10.3109/15360288.2014.941131.
[PMID] 25136897.
2013
Application of electronic medical record data for health outcomes research: a review of recent literature.
Expert review of pharmacoeconomics & outcomes research.
13(2):191-200
[DOI] 10.1586/erp.13.7.
[PMID] 23570430.
2013
Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation.
Journal of managed care pharmacy : JMCP.
19(9):789-98
[PMID] 24156648.
2012
A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
Journal of pain & palliative care pharmacotherapy.
26(2):153-64
[DOI] 10.3109/15360288.2012.671240.
[PMID] 22509775.
Grants
Jan 2024
– Jan 2025
Patterns and outcomes of antiplatelets use in addition to anticoagulants in atrial fibrillation patients undergoing PCI
Role: Co-Investigator
Funding: AMER HEART ASSOCIATION
Dec 2022
ACTIVE
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention
Role: Co-Investigator
Funding: EMORY UNIV
via CTRS FOR DISEASE CONTROL AND PREVENTION
Nov 2022
ACTIVE
Characterizing efficacy and safety of hormonal contraceptives by combining pharmacometrics and RWE
Role: Principal Investigator
Funding: BILL & MELINDA GATES FOUNDATION
Contact Details
Phones:
- Business:
- (352) 273-9933
Emails:
- Business:
- tianzejiao@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100496
GAINESVILLE FL 32610 - Business Street:
-
1889 Museum Road, Rm 6301
Gainesville FL 32611